At the US liver conference Inventiva will make a case for PPAR agonism, while Novo Nordisk and Gilead’s combo will be scrutinised in Nash.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
Ionis’s inhaled antisense candidate shows promising signs, with Arrowhead and Translate Bio also in the running.
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
As fresh data confirm the promise of RNAi technology in hepatitis B, Assembly brings on Arbutus for its combo strategy.